摘要
目的探讨艾拉莫德对降植烷（Pristane）诱导的系统性红斑狼疮（SLE）小鼠的治疗作用。方法将30只BALB／c小鼠随机分为正常对照组、模型对照组、艾拉莫德组，每组10只。采用腹腔注射0．5ml Pristane制作SLE模型。从造模后第2天开始，艾拉莫德组予以1mg／ml的艾拉莫德混悬液50mg-1·kg-1·d-1灌胃，其他两组均给予50mg-1·kg-1·d-1的生理盐水灌胃，共28周。定期测定各组小鼠前爪厚度、尿蛋白、血清抗ds—DNA抗体、补体c3、IL-6及IL-17水平。结果14周和28周后，艾拉莫德组小鼠前爪厚度明显低于模型对照组（P〈0．05），28周后与正常对照组相当；艾拉莫德组尿蛋白含量明显低于模型对照组（P〈0．01），但高于正常对照组（P〈0．05）。8周后，艾拉莫德组抗ds—DNA抗体缓慢升高，模型对照组持续快速上升并保持在较高水平，28周后艾拉莫德组仅为模型对照组的50％左右；14周和28周后，艾拉莫德组血清补体c3水平均明显高于模型对照组（P〈0．05）；治疗后艾拉莫德组血清IL-6和IL-17水平均低于正常对照组和模型对照组（P〈0．05）。结论艾拉莫德能有效地改善Pristane诱导的SLE小鼠的症状和相关实验室检查指标，为未来SLE的治疗提供一种新方法。
Objective To observe the therapeutic effect of iguratimod on mice of systemic lupus erythematosus（ SLE ） induced by Pristane. Methods 30 BALB/c mice were randomly divided into normal control group, model control group and iguratimod group, with 10 mice in each group. SLE model were induced by intraperitoneal injecting 0.5 ml Pristane. From the next day, iguratimod group was given 1 mg/ml iguratimod（50 mg-1·kg-1·d-1） by intragastric administration within 28 days,and the other two groups were given 50mg-1·kg-1·d-1 saline. The thickness of front foot,urinary protein concentration, levels of serum anti-ds-DNA antibody, complement C3, IL-6 and IL-17 were measured regularly. Results After 14 and 28 weeks, thickness of front foot of mice in the iguratimod group was lower than model control group （ P 〈 0.05 ） , was almost equal with the normal control group 28 weeks later. The urine protein of the iguratimod group was much lower than the model control group（ P 〈0.01 ） ,but higher than the normal control group（P 〈 0.05）. After 8-week therapy, the expression of anti-ds-DNA antibody in the model control group continued to rise rapidly and remained at a high level, but the iguratimod group just increased mildly, and was only about half of that in the model control group after 28 weeks. Level of serum complement C3 in iguratimod group was higher than model control group after 14 and 28 weeks（P 〈0.05）, but much lower than the normal control group after 28 weeks （ P 〈 0.05 ）. Levels of serum IL-6 and IL-17 in iguratimod group were lower than the other two groups after 14 and 28 weeks （ P 〈 0.05 ）. Conclusion Iguratimod can effectively improve symptoms and related indexes of laboratory tests in SLE mice induced by iguratimod,which provides a new treatment method of SLE in the future.
出处
《临床内科杂志》
CAS
2016年第11期773-775,共3页
Journal of Clinical Internal Medicine
基金
湖北省卫生和计划生育委员会医药科研项目（WJ2015MB042）
关键词
艾拉莫德
系统性红斑狼疮
治疗
Iguratimod
Systemic lupus erythematosus
Treatment
